PV Bulletin

EMA: Updated Day 215 PI Annex Submission Checklist for Post-Opinion Linguistic Review

EMA revised the submission checklist for Day 215 product information annexes (SmPC, labeling, package leaflet) to ensure consistency and quality before final authorization, reducing linguistic errors in safety warnings.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

MonitoringConfidence: high

What changed

EMA revised the checklist for submission of Day 215 product information annexes (SmPC, labeling, package leaflet) for post-opinion linguistic review under the centralized procedure.

Why it matters

Ensures consistency and quality in final safety information before authorization, reducing risk of linguistic errors in safety warnings.

Action needed

Update internal labeling workflows to align with the revised checklist; ensure submission documents meet updated formatting requirements for linguistic review.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

quarterly

Policy change details

Document type
Checklist
Policy status
revised
Publication date
2026-06-05
Policy change
This revised checklist is used by marketing authorization holders to ensure all necessary documents and annexes are correctly prepared and submitted for the post-opinion linguistic review at Day 215 of the centralized procedure.

Key changes

Updates the requirements and formatting checks for the final product information annexes, including SmPC, labeling, and package leaflet, to be submitted for linguistic review.

Affected workflows

Labeling

Responsible groups

Regulatory AffairsLabeling/Safety Teams

PV impact

Ensures consistency and quality in the final safety information provided in the SmPC and package leaflets before final authorization, reducing the risk of linguistic errors in safety warnings.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Update internal labeling workflows to align with the revised checklist; ensure submission documents meet updated formatting requirements for linguistic review.

EMA has updated its Day 215 submission checklist for post-opinion linguistic review. Marketing authorization holders must use this revised checklist to prepare and submit product information annexes (SmPC, labeling, package leaflet) to ensure formatting consistency and reduce linguistic errors in safety information.

What changed: EMA revised the checklist for submission of Day 215 product information annexes (SmPC, labeling, package leaflet) for post-opinion linguistic review under the centralized procedure.

Why it matters: Ensures consistency and quality in final safety information before authorization, reducing risk of linguistic errors in safety warnings.

Practical implication: Update internal labeling workflows to align with the revised checklist; ensure submission documents meet updated formatting requirements for linguistic review.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward